T2 Biosystems Announces Issuance of Patent Covering T2Candida® Assay
4/3/2013 10:54:54 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued a patent, number US8,409,807 (the ‘807 patent), covering T2Candida®, the Company’s flagship diagnostic test. T2Candida identifies sepsis-causing Candida species directly from whole blood at ~1CFU/mL sensitivity in approximately three hours compared with current methods that rely on blood culture and require two to five days. The patent describes the T2Candida test format and methodology to detect and identify Candida species in a whole blood sample.
comments powered by